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ABSTRACT 
Objective: To design a controlled topical delivery system of lornoxicam (LX) in order to enhance skin permeation and treatment efficacy. 
Nanosponges were selected as a novel carrier for this purpose.  
Methods: Nanosponges were formulated via the emulsion solvent evaporation method using ethyl cellulose (polymer) and polyvinyl alcohol 
(surfactant). Nanosponge dispersions were characterized for colloidal properties, entrapment efficiency and in vitro release study. The nanosponge 
formulation (LS1) was then incorporated into carboxymethyl cellulose sodium hydrogels and evaluated for pH, viscosity and in vitro drug release. 
Skin irritation was evaluated, and anti-inflammatory activity was assessed via rat hind paw edema method.  
Results: Nanosponges were in the nano-sized range and attained a uniform round shape with a spongy structure. LS1exhibited the highest LX 
release after 6 h, so it was incorporated as hydrogel. Formulated hydrogels showed acceptable physicochemical parameters (pH, drug content and 
rheological properties). Skin irritation testing proved LX-loaded nanosponge hydrogel formulation (G1) to be non-irritant. In vivo study revealed an 
enhanced anti-inflammatory activity of G1 for 6 h (p<0.001).  
Conclusion: The developed nanosponge hydrogel is an efficient nanocarrier for improved and controlled topical delivery of LX. 
Keywords: Ethylcellulose, Lornoxicam, Nanosponge, Topical delivery, Anti-inflammatory activity 
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INTRODUCTION 
Lornoxicam (LX) is a non-steroidal anti-inflammatory and pain-
relieving drug that is utilized for the treatment of joints 
inflammation, osteoarthritis, surgery, and sciatica [1]. LX inhibits 
both COX-1 and COX-2 and thus, has an inhibitory action on 
prostaglandin and thromboxane amalgamation [2]. However, LX is 
not preferred for oral administration for the following reasons. First, 
LX is classified according to the biopharmaceutical classification 
system (BCS) as a low solubility and high permeability drug (class II) 
[3, 4]. Therefore, it suffers low oral bioavailability, along with short 
plasma half-life (3 to 5 h) [5]. Second, its lipophilic nature and poor 
solubility in the acidic medium of the stomach cause local stomach 
irritation. Accordingly, topical delivery of LX will be advantageous, 
especially for patients that experience stomach problems [6, 7]. 
Nanosponges can be described as a colloidal structure based on 
hyper-crosslinked polymer comprising solid nanoparticles of nano-
sized cavities [8]. These colloidal nano-sized carriers have been 
proposed for drug delivery to solubilize lipophilic drugs and extend 
their release [9, 10]. Moreover, nanosponges enhance the 
bioavailability of drugs and modify pharmacokinetic parameters [11, 
12]. Furthermore, nanosponges are suitable means for delivering 
both lipophilic and hydrophilic substances due to their internal 
hydrophobic core and outer hydrophilic surface, offering excellent 
flexibility [13, 14]. Additionally, using hydrogel topical formulation 
as a delivery system can reduce irritation and improve retention on 
skin compared with other topical formulations [15, 16]. It was 
reported that hydrogel increased drug skin absorption and 
permeation 10 times higher than oil-based formulations [17]. 
Moreover, hydrogel unique property (porosity) provides beneficial 
sustained and controlled drug delivery of hydrophobic drug via 
suitable release mechanism [18]. 
The study aimed to design a topical delivery system of LX 
nanosponges hydrogels to promote the skin permeation of LX and 
consequently enhance treatment efficacy. For this purpose, 
lornoxicam nanosponges were prepared using ethyl cellulose as a 
polymer by emulsion solvent evaporation method. The developed 
nanosponges were then incorporated into a hydrogel. The 
formulations were evaluated for in vitro drug release. Finally, 
nanosponge hydrogel was evaluated using the method of 
carrageenan-induced rat hind paw edema to assess the potential of 
anti-inflammatory activity of LX nanosponge gel. 
MATERIALS AND METHODS  
Materials 
Lornoxicam was obtained as a gift from Hikma Pharmaceuticals 
Company (Egypt). Ethylcellulose (EC) (454.5 g/mol) and polyvinyl 
alcohol (PVA) of average molecular weight 40,000, were purchased 
from Sigma Aldrich (St. Louis, USA). Dichloromethane (DCM) was 
obtained from Algomhuria Medicine Trade Co. (Cairo, Egypt). Ethanol 
was acquired from ADWIC, (Egypt). Carboxyl methylcellulose sodium 
(CMC-Na) was kindly provided by EIPICO, (Egypt).  
Formulation of LX-loaded nanosponges  
Formulation of LX-loaded nanosponges was based on emulsion 
solvent evaporation [19]. Various amounts of ethyl cellulose and 
polyvinyl alcohol were utilized to prepare nanosponges (LS1-LS4). 
Dispersed phase was consisted of LX and EC and dissolved in 25 ml of 
dichloromethane. It was added in portions to 150 ml of an aqueous 
continuous phase containing a definite quantity of PVA. At that point, 
the blend was agitated at 1000 rpm for 2 h on an overhead stirrer 
(VELP, DLS stirrer, Italy). The formed nanosponges were exposed to 
filtration using Whatman® membrane filters PTFE pore size 0.5 μm) 
and dried in a hot oven for 2 h at 40 °C to remove any residual solvent. 
Nansponges were then kept in a vacuum desiccator. Table 1 shows the 
composition of LX loaded nanosponges formulations. 
Percentage entrapment efficiency (PEE) 
In a stoppered tube, nanosponges equivalent to 10 mg lornoxicam 
were taken and the drug was extracted with 50 ml of phosphate buffer 
solution (PBS) pH 6.8. The extracts were filtered using (Whatman® 
membrane filters PTFE pore size 0.5 μm) and transferred to 100 ml of 
a volumetric flask and the volume was completed with PBS pH 6.8 
[20]. The solutions were subjected to further dilution with the buffer 
and measured spectrophotometrically at 378 nm.  
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A calibration curve was plotted for lornoxicam in PBS (pH 6.8) in 
the range of 0.005-0.03 mg/ml at 378 nm. A good linear 
relationship was observed between the concentration of 
lornoxicam and its absorbance (R2= 0.998). The specificity of the 
analytical method was performed using a blank formula which was 
prepared from all the used excipients except drug to check if any 
component of the formulation or the dissolution medium could 
interfere with the absorbance of lornoxicam at the selected 
wavelength.  
Percentage entrapment efficiency was calculated by the following 
equation. PEE values given are the averages of three estimations. 
PEE =




Table 1: Formulation composition of lornoxicam-loaded nanosponges 
Formulation LS1 LS2 LS3 LS4 
Drug: EC: PVA 0.5:1:1 0.5:1:2 0.5:1:3 0.5:2:2 
LX 500 mg 500 mg 500 mg 500 mg 
EC(g) 1 g 1 g 1 g 2 g 
PVA (g) 1 g 2 g 3 g 2 g 
Dichloromethane (DCM) (ml) 25 ml 25 ml 25 ml 25 ml 
Dist. Water (ml) 150 ml 150 ml 150 ml 150 ml 
 
Particle size estimation of nanosponges 
Particle size of the dispersions was estimated utilizing a Zeta-sizer 
3000 PCS (Malvern Instr., England) outfitted with a 5mW helium-
neon optical device. Estimations were made at 25 °C, edge 90 °, run 
time in any event 180 s. The samples were appropriately dispersed 
in deionized water preceding the estimations. The particle size 
values given are the averages of 3 estimations over 5 min each. 
Surface morphology 
Scanning electron microscopy (Qunta FEG 250, FEI, USA) was 
utilized to analyze surface morphology working at 20 kV. 
Lornoxicam nanosponges were kept on carbon sticky tape and 
vacuum dried. SEM photographs were recorded at magnification of 
250X, 2000X, 5000X, 10000X. 
In vitro release of LX from nanosponges  
The in vitro release of LX from various nanosponges was performed 
utilizing the dialysis sac technique [21]. A sample equivalent to 1 mg 
of LX was put in the regenerated cellulose dialysis sac (Mw cut-off at 
12-14000 Da, Visking® dialysis tubing, UK) and both ends of the sac 
were firmly closed. The sac was immersed into a beaker containing 
150 ml PBS of pH 6.8 that served as the receptor cell. The beaker 
was placed in a shaker water bath at 37±0.5 °C and agitated at 50 
rpm. Samples were compared to a solution of lornoxicam (1 mg/5 
ml of PBS of pH 6.8; (LS0). For each sample, 3 ml was withdrawn 
from the receptor cell at 1, 2, 3, 4, 5 and 6 h and replaced by 
equivalent volumes of fresh release medium and kept up at a similar 
temperature. Drug concentrations were estimated 
spectrophotometrically at λmax 378 nm [22] against equivalent PBS 
as a blank using Jenway spectrophotometer (Model 6105UV/Vis, 
England). The amounts of drug released were calculated based on 
the calibration curve made. Samples were tested in triplicate, and 
the average concentration was adopted. 
Formulation of LX nanosponges loaded hydrogels 
Hydrogels were prepared by adding CMC-Na to water and stirring 
with a mechanical stirrer at approximately 600 rpm for 2 h. 
Different hydrogels were formulated as illustrated in table 2. The 
prepared dispersion was allowed to stand for 15 min to remove 
entrained air. At this point, LX nanosponges, propylene glycol and 
methanol, were added. Propyl and methylparaben were then added 
to the preparation as a preservative, and the volume was completed 
with water. 
 
Table 2: Formulation design of lornoxicam-loaded nanosponges hydrogels 
Ingredients Quantities % (W/W) 
G0 G1 G2 G3 
LX powder 0.5 - - - 
LX-loaded nanosponge (LS1) - 5 5 5 
Propylene glycol 40 40 40 40 
Methanol 8 8 8 8 
CMC-Na 1 1 1.5 2 
Propyl paraben 0.02 0.02 0.02 0.02 
Methyl paraben 0.18 0.18 0.18 0.18 
Double distilled water (q. s.) 100 100 100 100 
 
Physicochemical evaluation of LX-loaded nanosponge hydrogels 
Determination of pH of LX-loaded nanosponges hydrogels  
A digital pH meter (Model 420, ORION, USA) was used and 
calibrated utilizing standard buffers of pH of 4.0 and 7.0 before use. 
The glass electrode was immersed into the hydrogel and the pH 
readings were recorded at 25 °C [23]. 
Drug content estimation of LX-loaded nanosponge hydrogels 
One gram of LX nanosponge loaded hydrogels was blended with 100 
ml of PBS pH 6.8: methanol (50:50) (v/v) and sonicated for 10 min 
to acquire a transparent solution [24]. LX concentrations were 
measured spectrophotometrically at λmax 378 nm. The percent of 
drug content was estimated in triplicate for each formulation. 
Viscosity measurement of LX-loaded nanosponge hydrogels 
The viscosity of the fabricated gel bases was assessed using a viscometer. 
The rotation of the spindle was at 10 rpm. Anton Paar MCR502, 
SN81750818, and measuring cell: P-PTD200/TG, SN81720491, and 
measuring system: CP50-1/TG, SN31451 was used to measure the 
consistency of the fabricated gel bases. Samples were permitted to settle 
at room temperature for more than 30 min before estimation. 
In vitro release of LX from LX-loaded nanosponge hydrogels 
The in vitro release behavior of LX-loaded nanosponge hydrogels were 
investigated as prescribed previously compared to plain LX hydrogel. 
Skin irritation test 
The Draize test was performed to evaluate the irritation effect of 
developed LX-loaded nanosponge hydrogel formulation (G1) 
according to a previously published method. Animal ethical 
clearance certificate No. (181) was acquired by the Animal Ethics 
Committee from the Faculty of Pharmacy (Girl branch), Al-Azhar 
University, Cairo, Egypt, following recommendations for adequate 
care and use of laboratory pets (NIH publication No. 85-23, revised 
1985). Albino rats (n=6/group) were obtained from the animal 
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house of Faculty of Pharmacy (Girl branch), Al-Azhar University, 
Cairo, Egypt. Rats were acclimated for seven days prior to the 
experiment and maintained on food and water. Their backs were 
shaved a day before the experiment. Gel formulation (0.5 g) was 
applied on 4 cm2 of the hairless skin. Any changes on the skin were 
observed and recorded for 24, 48 and 72 h after the hydrogel 
application. Formalin was used as positive control and plain gel 
formulation was used as a negative control. The degree of erythema 
was graded based on the original scale of Draize test [15].  
Anti-inflammatory efficacy 
Anti-inflammatory efficacy of formulated hydrogel was assessed 
utilizing the technique of carrageenan-induced rat hind paw edema 
[25, 26]. Animal ethical clearance certificate No. (181) was acquired 
by the Animal Ethics Committee from the Faculty of Pharmacy (Girl 
branch), Al-Azhar University, Cairo, Egypt, following 
recommendations for adequate care and use of laboratory pets (NIH 
publication No. 85-23, revised 1985). Adult male albino rats (120-
150 g) were obtained from the animal house of Faculty of Pharmacy 
(Girl branch), Al-Azhar University, Cairo, Egypt. Rats were randomly 
divided into 2 groups (n= 6), acclimated for seven days prior to the 
experiment and maintained on food and water. Group 1 served as 
control and was treated with non-medicated plain gel. Group 2 and 3 
were treated with plain LX hydrogel (G0), and LX-loaded 
nanosponge hydrogel (G1), respectively. 
Throughout the experiment, LX-loaded nanosponge hydrogels and 
plain LX hydrogel (0.5 g) containing 5 mg of LX were applied to the 
plantar surface of the left hind paw by delicately rubbing 5 times 
with the index finger. Bandages occluded the application region and 
remained in position for 2 h. The bandages were separated, and the 
remaining gel was removed. 
In rats, acute inflammation (paw edema) was caused by the injection 
of 0.1 ml of 1% carrageenan solution in normal saline 
subcutaneously in the left hind paw sub-plant area and measured 
using a caliper device (micrometer). The injected paw thickness was 
evaluated immediately before carrageenan injection and at 1, 2, 3, 4, 
5 and 6 h after carrageenan injection (MandW. Ltd, Sheffild, 
England). The edema inhibition was calculated as a percent from 
edema thickness of the control group [25]. 
Statistical analysis 
The outcomes were analyzed statistically by means of one-way 
variance analysis (ANOVA), using GraphPad Prism version 8.1.2 
software to determine the significance of differences between 
groups; a P value less than 0.05 was regarded as statistically 
significant. 
RESULTS 
Percentage entrapment efficiency (PEE) 
Percentage entrapment efficiency has been established to ensure 
that an efficient amount of LX was entrapped in the nanosponges. 
Nanosponges had PEE ranged from 95.04%±5.14 to 99.32%±2.25 of 
LX. The results of PEE, Z-average, and PDI are shown in table 3. 
 
Table 3: Percentage entrapment efficiency, Z-average, and PDI of measured nanosponges (values are mean±standard deviation of n=3) 
Formulae LS1 LS2 LS3 LS4 
LX: EC: PVA 0.5:1:1 0.5:1:2 0.5:1:3 0.5:2:2 
Percent Entrapment efficiency (PEE)  98.87±4.25a 95.04±5.14a 98.97±3.87a 99.32±2.25a 
Z-average (nm)  545.5±1.19a 673.9±2.54b 818.7±1.66b 771.5±2.15c 
Polydispersity index (PDI)  0.320±0.05a 0.654±0.05b 0.623±0.03b 0.468±0.06c 
Means (within the same row) with different superscript letters are statistically significant at p>0.05. Means (within the same row) with same 
superscript letters are statistically non-significant at p>0.05. 
 
Particle size estimation of nanosponges 
Particle size measurement was conducted to ensure that particles of 
the nanosponges are of the nanometer range. It was observed that 
all prepared nanosponges were in the nano-sized range (average 
particle size values ranged from 545.5±1.19 nm to 818.7±1.66 nm), 
with a polydispersity index of<1 as shown in table 3. The increase of 
PVA proportion brought about a significant increase in particle size 
at p<0.001 (table 3). The increase of EC: drug ratio by 4 folds led to a 
significant increase of particle size at p<0.001.  
One-way ANOVA results showed that the EC: PVA ratio had a 
significant impact on the average particle size (Z-average (d. nm)) of 
nanosponges (p<0.001). 
Surface morphology 
The nanosponge morphology was analyzed by scanning Quanta FEG 
250 (FEI, USA) electron microscope (SEM). The SEM micrographs 
gave an idea regarding the morphological structure of nanosponges 
showing a round spongy structure with a smooth surface and fine 
holes (fig. 1). 
  
 
Fig. 1: SEM micrographs of nanosponges (LS4); (a) Magnification value (MV):5000x, (b) MV: 10000x, MV: (c) 2000x and (d) MV: 250x 
Shawky et al. 
Int J App Pharm, Vol 12, Issue 6, 2020, 217-223 
220 
In vitro release of LX from nanosponges and the kinetic analysis 
of the release data 
Lornoxicam's in vitro release profile from formulated nanosponges 
was conducted in phosphate buffer solution (PBS) (pH 6.8) using the 
dialysis sac method compared to LX solution as a control (fig. 2). 
Lornoxicam's release from its solution was slow and only 38.4%±1.9 
was released after 6 h.  
Nanosponge formulations improved LX release. Nanosponges (LS4, LS2, 
LS3, and LS1), has released about (52.09±5.1, 43.37±6.4, 45.13±5.7 and 
65.4±3.4) %, respectively of LX during 6 h. Nonosponges were found to 
enhance the release by several folds [19]. Increasing PVA concentration 
significantly reduced the amount of LX released after 6 h at p<0.01 [27]. 
LS3, with the largest particle size of 818.7±1.66 nm, showed the least 
amount of drug release, while LS1 showed the highest release after 6 h, 
so it was selected for further study. 
It was observed that the in vitro release model best fitted to Hixon-
Crowell release kinetic as their (r) value gave a higher value and 
ranges between 0.9929-0.9980. The Korsmeyer-Peppas release 
exponent (n) ranged between 0.67-0.79. 
 
 
Fig. 2: In vitro release profiles of LX from LX-loaded nanosponges in comparison with control Ls0 (LX solution 1 mg/ml PBS pH 6.8) in PBS 
(pH 6.8) at 37 °C±0.5 °C. The values are the mean±standard deviation of n=3. Abbreviations: Ls, formulations 
 
Physicochemical evaluation of LX nanosponge loaded hydrogels 
The pH values of LX-loaded nanosponges hydrogels were ranged 
between 7-8.1. LX content in the prepared hydrogels of nanosponges 
ranged between 85.9%-93.12%. Fig. 3 illustrates the viscosity 
measurement of LX-loaded nanosponges hydrogels. The samples of G1, 
G2 and G3 (detailed composition is presented in table 2) were found to 
be non-Newtonian liquids with shear-thinning properties. The viscosity 
of formulated hydrogels decreased with increasing the shear rate, as 
shown in fig. 3. It was found that G3 (CMC-Na 2%), has a higher viscosity 
than other formulations, as indicated by the yield stress values. The yield 
stress values in Pa for G3, G2 and G1 were 105, 38 and 8, respectively. 
 
 
Fig. 3: Viscosity measurement; (a) Shear rate effect on the viscosity of various gel formulations and (b) Shear rate effect on the shear 
stress of various gel formulations 
 
 
Fig. 4: In vitro release profiles of LX from topical hydrogels integrating LX-loaded nanosponges in phosphate buffer solution (pH 6.8) at 37 
°C±0.5 °C. The values are the mean±standard deviation of n = 3. Abbreviations: G, gel formulations 
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Fig. 5: Comparative percent edema inhibition of lornoxicam gel with lornoxicam nanosponge gel. The values are expressed as 
mean±standard deviation (n=6). Abbreviations: G: Gel formulations, ns: values are not significant statistically compared to the control 
group where P>0.05, ** Values are significantly different compared to control group where P<0.001 
 
In vitro release of LX from LX-loaded nanosponges hydrogels 
Fig. 4 shows the in vitro release data of LX from various nanogels 
compared to the control LX gel (G0). It was found that G1 formulation 
released 39.81%±1.11, 60.41%±2.5 and 78.52%±8.4 after 2, 4 and 6 h, 
respectively. Furthermore, it was observed that amount of LX releases 
from G2 and G3 was lower than that released from G1.  
Statistically, G1 showed a higher percentage of LX released 
compared to other gels at p<0.001, after 2 and 4 h. It can be 
observed that the release of formulations (G1, G2, and G3) exhibited 
Fickian transport according to Korsmeyer-Peppa's release model, 
which means that release always associated with diffusion 
mechanism while G0 exhibited non-Fickian transport. 
Skin irritation 
The mean erythemal score of the tested formulation G1 was 0.00 
which indicated G1 was non-irritant to the skin as revelead by 
absence of erythema on the shaved skin. 
Anti-inflammatory activity 
Fig. 5 illustrates the anti-inflammatory activity LX-loaded 
nanosponge hydrogel (G1) compared plain LX gel (G0). Lornoxicam-
loaded nanosponge hydrogel (G1) produced % edema inhibition 
(66.63%) after 3 h while G0 produced only (42.11%). Maximum % 
edema inhibition of G1 was observed after 5h (92.91%). After 6 h, 
G0 showed % edema inhibition (18.21%) while % edema inhibition 
of G1 was (60.15%). Percent edema inhibition of G1 was 
significantly higher at p>0.001 as compared to G0 at 2, 3, 4, 5 and 6 
h. Moreover, it can be observed that the anti-inflammatory effects of 
G0 and G1 are correlated to the in vitro release results. For example, 
G1 showed LX release of 50.78% and generated 66.63% edema 
inhibition while G0 released 32.82% of LX and generated only 
42.11% edema inhibition at 3 h. Furthermore, G1 produced the 
maximum edema inhibition at 5 h (92.91%), which in correlation 
with 69.25% of LX released. 
DISCUSSION 
The main scope of this study was to develop a new topical delivery 
system of LX using nansopnges as colloidal carriers suitable for such 
delivery. The colloidal properties of developed nanosponge 
formulations were investigated. Percentage entrapment efficiency 
values ensured that an efficient amount of LX was entrapped in the 
nanosponges. Particle size estimation confirmed that prepared 
nanosponges were in the nano-sized range with a polydispersity 
index of<1. The mean particle size of nanosponges was directly 
influenced by the drug: EC proportion. This may be attributed to the 
higher drug content and the lower amount of polymer available per 
nanosponge for encapsulation. Consequently, the thickness of the 
polymer wall is reduced and nanosponges are smaller [27]. The 
increase of EC ratio by 4 folds in LS4 led to a significant increase of 
particle size at p<0.001 and this can be explained by the thick 
polymer arrangement caused by the polymer proportion increase. 
The high viscosity prevents the breaking of the emulsion into 
smaller droplets. Therefore, nanosponges with larger particle size 
are formed [28, 29]. On the other hand, the low concentration of the 
EC increases the diffusion of dichloromethane (internal phase) into 
the aqueous solution (external phase), decreasing time needed to 
form droplets and thus reducing the particle size [13]. Moreover, 
increased particle size with increasing PVA proportion may be 
attributed to frothing, which leads to aggregates formation [15]. SEM 
micrographs revealed that the prepared nanosponges had a uniform 
round shape with a spongy structure and smooth surface. The fine 
holes present on nanosponge surface could be related to the 
diffusion of dichloromethane from the surface of the nanoparticles 
during the preparation phase [29, 30]. In vitro release showed that 
LX's release from its solution was slow after 6 h and this may be 
attributed to its low solubility [31]. Nanosponge formulations 
improved LX release by several folds and this could be attributed to 
the disruption and diffusion of LX from the external surface of 
nanosponges at initial stage followed by a slow and sustained 
release of LX during 6 h [32]. Increasing PVA concentration 
significantly reduced the amount of LX released [27]. Such decrease 
could be explained by an increase in the thickness of the 
nanosponges’ matrix as a result of increasing polymer concentration 
[33]. Increased thickness of nanosponge wall resulted in an 
extended diffusional way and thus, decreased LX release rates [13]. 
LS1 showed higher release after 6 h due to having the smallest 
particle size (545.5±1.19 nm), which was likely provided a large 
surface area for drug release, so it was selected for further study. It 
was noticed that the dissolution rate of nanosponges is 
extraordinarily affected by their surface area, porosity and particle 
size distribution [33]. Additionally, the drug release may be affected 
by the size of nansopnge holes that carry drug molecules [34]. The in 
vitro release kinetic data indicated anomalous non-fickian diffusion 
suggesting that release was controlled by a combination of diffusion 
and polymer relaxation. These results clarified that the drug release 
was controlled by the rate of solvent penetration into a non-
swellable water-insoluble polymer such as ethylcellulose which 
controls drug release through the micropores present in their 
framework structure [35].  
The physicochemical evaluation of LX nanosponge loaded hydrogels 
showed that hydrogels possessed both acceptable drug content and 
pH for topical application. Sample consistency is a significant 
parameter for topical formulations as it has to be applied in thin 
layers to the skin. It is, therefore beneficial to formulate a non-
Newtonian flow system due to its low flow resistance when used 
under elevated shear circumstances [29]. The hydrogel samples 
were found to be non-Newtonian and shear-thinning liquids. It 
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means that the viscosity decreased by increasing the shear rate. G3 
(CMC-Na 2%), showed a higher viscosity than other hydrogels 
indicating lower spreadability.  
Developed nanogels revealed an enhanced release pattern compared 
to nanosponge formulations. This may be attributed to the 
penetration enhancement ability of propylene glycol incorporated in 
the nanogel formulations [36]. Moreover, it was found that G1 
formulation released higher LX amount compared to G2 and G3 and 
this may be attributed to increased viscosity associated with 
increasing CMC-Na concentration as confirmed by the viscosity 
measurements [37]. Furthermore, the release pattern of developed 
nanogels exhibited Fickian transport according to Korsmeyer-
Peppa's release model, which means that release always associated 
with diffusion mechanism while G0 exhibited non-Fickian transport.  
Furthermore, the Draize test revealed that the developed 
formulation was non-irritant to the skin, indicating its safe 
application. Anti-inflammatory assessment is based on the 
formulation’s efficacy to inhibit the edema generated in hind paw 
after Carrageenan treatment. Maximum % edema inhibition of 
developed nanogel formulation was observed after 5 h which 
indicate controlled and sustained anti-inflammatory response. After 
6 h, plain LX gel (control group) showed low % edema inhibition 
compared to developed formulation. Developed nanogel produced 
significant enhancement anti-inflammatory activity compared to the 
control group for 6 h. Moreover, it can be observed that the anti-
inflammatory effects of G0 and G1 are correlated to the in vitro 
release results. For example, G1 showed a LX release of 50.78% and 
generated 66.63% edema inhibition at 3 h. G0 released 32.82% of LX 
and generated only 42.11% edema inhibition at the same time. 
Furthermore, G1 produced the maximum edema inhibition at 5 h 
(92.91%) in correlation with 69.25% of LX released achieving a 
controlled anti-inflammatory response [38]. The findings support 
that nanosponges improved skin permeation and consequently 
enhanced the anti-inflammatory response [39].  
CONCLUSION 
Lornoxicam was efficiently encapsulated in EC nanosponge (drug: EC: 
PVA 0.5:1:1) using the emulsion solvent evaporation technique, 
followed by its incorporation into CMC-Na hydrogel. Formulated 
nanosponges possessed appropriate particle size with a sponge-like 
structure that was preserved within the colloidal gel. Nanosponge-
based hydrogels improved and controlled LX release for 6 h compared 
to control. The developed formulation showed no irritation effect on 
rat skin. Furthermore, formulated nanosponges demonstrated in vivo 
anti-inflammatory response that reached its maximum in 5 h 
indicating improved and controlled effect of the topical application for 
six hours. It could be inferred that EC based nanosponges would be an 
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